Trial · NCT04984837
Registered outcomes35
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 35
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | median modified progression-free survival (mPFS) - CT-based | 5,5 years. | time from randomization until one of the following events occurs, whichever comes first: 1. Disease progression (PD) 2. Administration of any additional unplanned anti-lymphoma treatment (except allogeneic or autologous hematopoietic cell transplantations (HCT)) 3. Relapse after achievement of CR 4. Death due to any cause. PD and relapse will be evaluated according to Lugano 2014 criteria (CT-based). |
| Secondary | median modified progression-free survival (mPFS) - PET-based | 5,5 years. | |
| Secondary | Number of Adverse Events | 5,5 years. | |
| Secondary | overall survival (OS) | 5,5 years. | |
| Secondary | complete response rate (CRR) Lugano 2014 criteria (CT-based) | 5,5 years. | |
| Secondary | complete response rate (CRR) Lugano 2014 criteria (PET-based) | 5,5 years. | |
| Secondary | overall response rate (ORR) Lugano 2014 criteria (CT-based) | 5,5 years. | |
| Secondary | overall response rate (ORR) Lugano 2014 criteria (PET-based) | 5,5 years. | |
| Secondary | response rate assessed by Deauville criteria | 5,5 years. | |
| Secondary | duration of response (DOR), | 5,5 years. | 1. Disease progression (PD) 2. Administration of any additional unplanned anti-lymphoma treatment (except allogeneic or autologous hematopoietic cell transplantations (HCT)) 3. Relapse after achievement of CR 4. Death due to any cause |
| Secondary | rate of patients proceeding to allogenic stem cell transplantation | 5,5 years. | |
| Secondary | Pharmacokinetics of lacutamab with GemOx : Maximal Concentration of lacutamab (Cmax) | 1 month (1 cycle) | |
| Secondary | Pharmacokinetics of lacutamab with GemOx : Trough Concentration of lacutamab (Ctrough) | 1 month (1 cycle) | |
| Secondary | Pharmacokinetics of lacutamab with GemOx : Maximal Concentration of lacutamab (Cmax) | 2 months (2 cycles) | |
| Secondary | Pharmacokinetics of lacutamab with GemOx : Trough Concentration of lacutamab (Ctrough) | 2 months (2 cycles) | |
| Secondary | Pharmacokinetics of lacutamab with GemOx : Maximal Concentration of lacutamab (Cmax) | 3 months (3 cycles) | |
| Secondary | Pharmacokinetics of lacutamab with GemOx : Trough Concentration of lacutamab (Ctrough) | 3 months (3 cycles) | |
| Secondary | Pharmacokinetics of lacutamab with GemOx : Maximal Concentration of lacutamab (Cmax) | 7 months (7 cycles) | |
| Secondary | Pharmacokinetics of lacutamab with GemOx : Trough Concentration of lacutamab (Ctrough) | 7 months (7 cycles) | |
| Secondary | Pharmacokinetics of lacutamab with GemOx : Maximal Concentration of lacutamab (Cmax) | 9 months (9 cycles) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04984837/registered